ASH 2020 | Apollo: pomalidomide plus dexamethasone, with/without daratumumab in R/R MM
Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses the initial results of the APOLLO trial, a Phase III study (NCT03180736) of subcutaneous daratumumab (dara) plus pomalidomide and dexamethasone (Pd), compared to Pd alone in relapsed/refractory multiple myeloma. Dara is an anti-CD38 antibody, shown in earlier studies to establish deep responses in combination with pomalidomide. The data supported the use of D-Pd as an effective treatment for relapsed/refractory myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Transcript (edited for clarity)
Another trial that I would like to discuss is the APOLLO trial. The APOLLO trial has been performed in the European Myeloma Network. It is a trial in relapsed/refractory patients with multiple myeloma. The treatments in this randomized trial consisted of pomalidomide and dexamethasone with daratumumab or without daratumumab. The primary endpoint was progression-free survival. In the analysis that was done and submitted to ASH, it’s also observed that the response rate is significantly higher in patients receiving dara + pom-dex...
Another trial that I would like to discuss is the APOLLO trial. The APOLLO trial has been performed in the European Myeloma Network. It is a trial in relapsed/refractory patients with multiple myeloma. The treatments in this randomized trial consisted of pomalidomide and dexamethasone with daratumumab or without daratumumab. The primary endpoint was progression-free survival. In the analysis that was done and submitted to ASH, it’s also observed that the response rate is significantly higher in patients receiving dara + pom-dex. Also, a second observation was that progression-free survival is better. We also observed MRD negativity in patients. That was four times higher than in patients without daratumumab, 9 against 2%. This trial just had its first analysis. The results are very promising. They opened the way to treat patients in relapse/refractory situation with dara + pomalidomide and dexamethasone. We need longer follow-up to make any conclusions about the overall survival.
Read more...
